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S U M M A R Y
Leishmaniasis is a vector-borne protozoan infection with a wide clinical spectrum, which ranges from
asymptomatic infection to fatal visceral leishmaniasis. A review of the recent literature indicates a sharp
increase in imported leishmaniasis cases in developed, non-endemic countries over the last decade, in
associationwith increasing international tourism,military operations, and the inﬂux of immigrants from
endemic countries. South America is the main area for the acquisition of cutaneous leishmaniasis, and
adventure travelers on long-term trips in highly-endemic forested areas are at particular risk. Popular
Mediterranean destinations are emerging as the main areas of acquisition of visceral leishmaniasis for
European travelers. Leishmaniasis should be considered in patients presentingwith a compatible clinical
syndrome and a history of travel to an endemic area, even if this occurred several months or years ago.
Appropriate counseling should be provided to adventure travelers, military personnel, researchers, and
other groups of travelers likely to be exposed to sandﬂies in endemic areas.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Leishmaniasis is a vector-borne protozoan infection with a
clinical spectrum that includes asymptomatic infection and three
main clinical syndromes: visceral leishmaniasis (VL; also known as
‘kala-azar’), cutaneous leishmaniasis (CL), and mucosal leishmani-
asis (ML). The disease remains a public health problem worldwide,
affecting approximately 12 million people in 88 countries where
350 million people live, mainly in remote rural areas and
underserved urban areas. Based on geographical distribution,
leishmaniasis is divided into Old World and New World
leishmaniasis. Infection is transmitted through hematophagus
sandﬂies of the Phlebotomus genus in the Old World and the
Lutzomyia genus in the New World. Infection can also be blood-
borne, and can occur following organ transplantation or transmit-
ted congenitally. There are more than 17 Leishmania species known
to infect humans.1
VL is endemic in more than 60 countries in tropical and
subtropical areas, and in Mediterranean countries; however 90% of
the 500 000 new cases that occur every year concern six countries
only – India, Bangladesh, Nepal, Brazil, Ethiopia, and Sudan.1 VL is
caused by Leishmania donovani in the Indian subcontinent, Asia, and
Africa, Leishmania infantum in the Mediterranean basin, and* Corresponding author. Tel.: +30 210 5212 175; fax: +30 210 5212 177.
E-mail address: helen-maltezou@ath.forthnet.gr (H.C. Maltezou).
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and South America the disease is zoonotic and affectsmainly infants
and young children.3 In these countries stray and domestic dogs are
themain reservoir for infection, and theVLcycle is sustained inwell-
deﬁned foci by a high (up to 25%) prevalence of canine leishmaniasis
and abundant sandﬂies.4,5 In the Indian subcontinent and Africa, VL
is anthroponotic (human-to-human transmission through sand-
ﬂies) and affects adults and children.1 In the last decade
leishmaniasis expanded or emerged in several foci worldwide due
to climate and human factors (e.g., urbanization, deforestation).1
Models predict that sandﬂies will further expand with global
warming.6 The widespread emergence of resistance to pentavalent
antimonials in India, where half of VL cases occur globally, and the
emergence of HIV co-infection (in Northwest Ethiopia up to 30% of
VL cases are HIV-co-infected) compromise its control.7,8
CL is endemic in more than 70 countries, with an estimated of
1.5–2 million new cases every year.1 Afghanistan, Syria, and Brazil
are the main foci. CL is more common in rural areas in settings
ranging from rainforests to arid regions; however it is becoming
increasingly reported in urban and peri-urban areas of the Old and
NewWorld.1 CL is caused by Leishmania tropica, Leishmania major,
and L. infantum in the Old World and by Leishmania braziliensis,
Leishmania guyanensis, Leishmania panamensis, Leishmania peruvi-
ana, Leishmania mexicana, Leishmania amazonensis, and Leishmania
venezuelensis in the New World.1 Although ML develops in only a
small number of patients with NewWorld CL, its course is chronic
and may be life-threatening.1ses. Published by Elsevier Ltd. All rights reserved.
A. Pavli, H.C. Maltezou / International Journal of Infectious Diseases 14 (2010) e1032–e1039 e1033International travel is growing rapidly worldwide. It has been
estimated that approximately 1 billion international travel
movements will occur up to the end of 2010 and 1.6 billion up
to 2020, most of which will take place in tropical and subtropical
areas.9 More than half of international travelers are traveling for
leisure, however an increasing number of travelers are immigrants
visiting friends and relatives in tropical and subtropical areas.
International travelers are increasingly involved in adventure
travel and outdoor activities,2,10 which render them at increased
risk of contracting leishmaniasis. Over the last decade there has
been an increase in articles on imported cases in developed, non-
endemic countries in association with increasing international
tourism, military operations, the inﬂux of immigrants from
endemic countries, and HIV-infected persons.2,11–19 CL is emerging
among travelers involved in outdoor activities in endemic areas,
and is one of the top 10 diseases among tourists returning from
tropical countrieswith skin problems.12 A signiﬁcant number of VL
cases have also been reported among travelers in recent
years.2,15,16,20
In non-endemic countries the management of leishmaniasis
remains a challenge for physicians, and delayed diagnosis and
inappropriate treatment are frequently encountered.11,13,15,16 This
article reviews travel-acquired leishmaniasis with a focus on
epidemiology and treatment. We searched the PubMed database
for the period 1980 through January 31, 2010 using the words
‘leishmaniasis’, ‘imported’, ‘travelers’, and ‘travel-acquired’. Arti-
cles presenting original data on imported leishmaniasis cases were
included in our review, and review articles were also studied.
2. Leishmaniasis in international travelers
A sharp increase in imported leishmaniasis cases in industrial-
ized, non-endemic countries, in association with increasing
international travel, military activities, and immigration has been
published in the last decade. We found 29 articles presenting
original data on travel-acquired leishmaniasis.2,11,13–39 Of these,
21 referred to international travelers, including some cases of
military personnel, while eight articles reportedmilitary personnel
exclusively. The characteristics of these cases are shown in Tables 1
and 2. Out of 2577 published travel-acquired leishmaniasis cases,
80% concerned military personnel, of which almost all (99%)
occurred from the year 2000 onwards.With regard to international
travelers, more than 50% of cases for whom the year of acquisition
of infection was reported occurred after 2000. Given the lack of
familiarity of physicians in non-endemic countries with leishman-
iasis and the fact that CL frequently self-heals, many cases may
have remained unrecognized. It is expected that the risk and
therefore the incidence of leishmaniasis among international
travelers is likely to increase in the coming years, given the
increasing popularity of travel and ecotourism in endemic
destinations, as well as military operations and immigration. In
the UK an increase in the annual number of imported CL cases has
been noted – from 4 to 18 per year between 1995 and 2003.13 The
rise of L. braziliensis CL cases diagnosed in the UK is associated with
the increasing number of travelers to South America (3.5-fold
increase from 1995 to 2003), mainly to highly endemic foci in
Bolivia and Belize.13
The area of acquisition of infection reﬂects travel destinations of
the population studied. In the USA most CL cases in civilians are
acquired in Mexico and Central America, with an estimated
incidence of one CL case treated with antimonials per 1000
travelers to Suriname and one per 1 million travelers to Mexico.17
According to our review (Table 1), the NewWorld accounts for 59%
of imported cases in non-endemic countries. Data from the
Geosentinel database for 1996–2004 show that CL is among the 10
most frequent dermatologic disorders encountered in returnedtravelers, and South America is the main area of acquisition of CL,
followed by Central America.40 Data from the German Surveillance
System for Imported Diseases collected during 2001–2004 indicate
that the vast majority (81%) of VL cases were acquired in the
countries of southern Europe, while almost half (48%) of CL cases
were acquired in South America.28 Germans on holiday accounted
for most imported cases in Germany, however a non-negligible
(19%) number were non-European immigrants.28 In this study, the
relative risk for acquisition of leishmaniasis per geographic area
compared with southern Europe was estimated at 22.7 for South
America, 5.4 for Asia, and 2.1 for Africa.28 Similarly, imported VL
cases to the UK during 1985–2004 were contracted in Italy, Spain,
Greece, Cyprus, and Malta, and tourists accounted for 55.5% of
them, while the remaining patients were immigrants; however
after 2000 all patients were tourists.16 Of note, few imported cases
are acquired in countries where the vast majority of the global
burden of leishmaniasis occurs – Indian subcontinent, East Africa,
and the Middle East. This highlights the different epidemiologic
proﬁle between indigenous and imported cases.
Imported leishmaniasis is most frequently diagnosed among
tourists and travelers traveling for professional reasons (research-
ers, construction workers, military personnel), as well as immi-
grants and expatriates (Table 1). Ecotourists, adventure travelers,
soldiers, journalists, photographers, and researchers on long-term
trips who work in forests during the nighttime (e.g., geologists,
veterinarians) are at high risk for acquiring CL.21 In a 5.3-year study
of American CL in US travelers, 39% occurred among tourists and
46% among scientists traveling in Central and South America. This
represented one thousandth of the estimated annual cases of
American CL in the USA (n = 59,300).17 Long-term travel in
endemic areas is a risk factor for the acquisition of leishmaniasis,
however even short-term travelers may contract the disease. Men
account for 64–71% of all travel-acquired leishmaniasis
cases;17,20,21,28 this is attributed to the overrepresentation of
men in high-risk outdoor activities.
More than 80% of imported leishmaniasis cases in returned
travelers concern CL (Table 1). ML is rarely reported among
travelers, however nowadays ML is increasingly identiﬁed among
travelers to South America,with the vastmajority of cases acquired
in rural or forest areas of the Amazon basin in Bolivia, where highly
endemic foci for L. braziliensis exist.13,19 VL is also rare in
travelers.40 Imported VL cases usually concern adult male tourists,
HIV-infected persons, or children.2,15,16,20,28 The diagnosis of CL or
ML in returned travelers has been delayed several months or years
after the onset of symptoms; similar delays have been reported for
VL cases in non-endemic countries.13,16,17,20–22,27,28 In contrast, in
endemic countries VL is diagnosed as early as 2 weeks after the
onset of symptoms.4 Inappropriate management of leishmaniasis
is also common.11,13,26 One patient with New World CL consulted
six physicians, underwent two skin grafts, and paid a total of US$
6600 before the correct diagnosis was considered.14
International travelers are frequently unaware about leish-
maniasis and the appropriate protective measures. A survey
conducted among 373 travelers in Manu National Park, Peru,
revealed that only 6% of them had heard of leishmaniasis, although
96.5% had received pre-travel advice and 97.5% used protective
measures.41 In another survey conducted among 58 American
travelers with New World CL, 53% reported that they have heard
about leishmaniasis, however only 29% were aware of protective
measures; of note, 63% of the 47% travelers who had never heard
about leishmaniasis had received pre-travel advice.17
Travel and immigrationmay also contribute to the introduction
of new Leishmania species in an already endemic area.42 CL has
been reported in patients with no history of travel to an endemic
area, through importation of sandﬂies with various transportation
means from endemic areas.42 Importation of canine VL to a naı¨ve
Table 1
Published cases of travel-acquired leishmaniasis
Importation
country [Ref.]
Time period No. of
cases
Area of infection Travel type Immuno-
compromised
Age (years) Male sex Cases per clinical
form CL/ML/VL/MCL
Time to diagnosis (months)/
outcome after treatment
Australia [15] 2005–2007 20 Asia, Africa,
southern Europe,
South America
Immigrants (45%),
travelers (55%)
10% 8–59 85% 18/-/2/- NA/NA
Australia [29] 2004 1 Southern Europe Tourist 18 100% -/-/1/- 12 months/cured
Canada [26] 2003 1 Africa Tourist 54 100% 1/-/-/- 3 months/cured
France [14] 2003–2005 35 Africa NA 1–70 45.7% 35/-/-/- 1–12 months/15
complete clinical
response,a 20 failed
to respond
France [21] 1992–2000 39 Old World and
New World
Travelers, immigrants (NA) 38b 64% 39/-/-/- Up to 10 months/35
cured, 2 self-healed,
2 not assessed
Germany [20] 2000–2002 58 Southern Europe,
South America,
Asia, Middle East,
Africa
Tourists (50%), immigrants,
workers (7%)
20.6%c 8 mo–70 70.6% 35 (CL+ML)/23/- 1–16 months/42 cured,
2 improved, 3 no cure,
8 unknown, 1 relapse,
2 no relapse at 6–8
months
Germany [24] 2009 1 Southern Europe Tourist 66 100% 1/-/-/- 3 months/cured
Germany [28] 2001–2004 42 Southern Europe,
Africa, Asia,
Middle East,
South and
Central America
Tourist, expatriates,
immigrants (NA)
12%d 1–75 69% 23/3/16/- 0–30 months/5 treatment
complications, 1 died
(with HIV)
Israel [27] 2003 1 South America Traveler (NA) 26 100% -/1/-/- 0.5 months/improved
Israel [37] 1998–2001 12
South America
Travelers 23–29 92% 12/-/-/- 1–3/cured
Israel [38] 2004–2005 7 South America Travelers 21–24 71% 7/-/-/- NA/cured
Israel [39] 1994–1996 10 South America Travelers 22–29 80% 10 0.6/NA
Italy [11] 2001–2002 4 Asia, Africa,
Central America
Tourists (75%), soldier (25%) 23–63 100% 3/1/-/- Up to 1 month/cured
Spain [2] 1995–2008 18 Central and
South America,
Africa, Asia
Migrants (38%), travelers (62%) 11% 17–55 66.6% 12/4/2/- 0.5–48 months/11 good
response, 1 slow response,
2 relapse, 2 complications,
3 no follow-up
UK [16] 1985–2004 39 Southern Europe,
Africa, Asia,
South America
Immigrants–refugees (45.5%),
tourists (55.5%)
38.4%e 2–66 66.6% -/-/39/- 1–11 months/34 cured,
3 died while on treatment, 2
refused treatment
UK [19] 2004 3 South America Tourists (100%) 17–38 33.3% -/-/-/3 0–1 month/cured
UK [13] 1995 –2003 85 South America Tourist (most), military (NA) 17–81 68% 79/6/-/- 0.5–2 months/cured (data
available for ML only)
UK [22] 1997–2000 42 South America,
southern Europe,
Asia, Africa
Tourists, military, scientiﬁc work,
immigration (NA)
NA 64.2% 42/-/-/- 21 patients <3 months,
3 patients 3–6 months,
7 patients 6–12 months, 4
patients >12 months/cured
USA [17] 1985–1990 59 Central America,
South America
Travelers (39%), scientists (46%)
(long-term) (NA)
3–64 67.7% 59/-/-/- 13–1022 days/NA
USA [25] 2007 1 South America Tourist 50 100% -/1/-/- 1 month/cured
Venezuela [23] 2001–2006 29 South America Travelers (100%) 7–64 NA (most males) 29/-/-/- NA/NA
CL, cutaneous leishmaniasis; ML, mucosal leishmaniasis; VL, visceral leishmaniasis; MCL, mucocutaneous leishmaniasis; NA, not available.
a Twenty-seven patients with Leishmania major CL were treated with oral ﬂuconazole.
b Mean age.
c Six cases of VL were HIV-seropositive.
d Six cases (ﬁve VL and one CL) were HIV-seropositive.
e Thirteen cases were HIV-seropositive.
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A. Pavli, H.C. Maltezou / International Journal of Infectious Diseases 14 (2010) e1032–e1039 e1035area may have public health consequences. One case of canine VL
was imported to French Guiana, most probably from France, with a
recorded secondary case.43
3. Clinical manifestations
Clinical manifestations vary by Leishmania species, area of
acquisition of infection, and host factors. CL is the most common
form of leishmaniasis. VL is themost serious form of leishmaniasis.
Infection with viscerotropic Leishmania species usually results in
asymptomatic or mild illness followed by spontaneous resolution.
Only one out of 30–100 infected cases develop typical VL. Factors
predisposing to development of typical VL include young age,
malnutrition, poverty, immune deﬁciency, and high leishmanial
load.1
Progression to typical VL usually takes 2–8 months or
occasionally longer, however cases as short as 2 weeks after
infection have been reported.1 Typically the patient develops fever,
weakness, anorexia, weight loss, pallor, hepatosplenomegaly
(usually splenomegaly predominates), lymphadenopathy, and
progressive deterioration.3 As a rule, patients almost always
present with fever, hepatosplenomegaly, and thrombocytopenia.4
Children may also present with growth retardation.4 Late ﬁndings
include epistaxis, gingival hemorrhage, abdominal distension,
edema, and ascites.1 Laboratory ﬁndings include normocytic–
normochromic anemia, neutropenia, thrombocytopenia, hyper-
gammaglobulinemia, hypoalbuminemia, and increased hepatic
transaminases.4 Occasionally VL may manifest as acute hepatitis,
cholecystitis, hemophagocytic syndrome, and Guillain–Barre´
syndrome.3 If not treated, VL is almost always fatal. Death is
caused by hemorrhage, severe anemia, or secondary infection.1
American military personnel who served in the Middle East in the
early 1990s developed a viscerotropic syndrome following
infection with L. tropica characterized by prolonged fever, fatigue,
cough, abdominal pain, and diarrhea.44
In the context of HIV co-infection, VL is usually the result of
relapse after years of latency or represents a newly-acquired
infection. Leishmaniasis may also be transmitted through needle
sharing. HIV-infected patients usually have higher parasite loads
and atypical symptoms (e.g., gastrointestinal), especially with low
CD4 cell counts. This group of HIV-infected patients responds
poorly to treatment and rates of relapse are high, regardless of
treatment used.45,46
CL may manifest with one or more skin lesions on the
exposed body within several weeks or months after the sandﬂy
bite.14,17,19 Occasionally the lesions may appear months or years
later. New World CL has variable clinical manifestations, ranging
from ulcerative skin lesions to destructive mucosal inﬂamma-
tion, and is often accompanied with local lymphadenopathy,47
while Old World CL may present with multiple lesions.48 The
initial lesion is usually a papule, which subsequently progresses
to nodule and then to ulcer during the next 1–3
months.1,11,17,19,21,22,24,26,27 The face, upper limbs, and lower
limbs are the most frequently involved.2,17,22 Leishmanial ulcers
are typically painless and grow slowly with a granulomatous or
crusted base and raised margins.49 Painful lesions may occur in
the context of bacterial superinfection. Uncommon manifesta-
tions include lupoid, sporotrichoid, psoriasiform, mycetoma-
like, and erysipeloid forms.1 Occasionally CL may manifest as
isolated lymphadenopathy19,49 or progress into disseminated CL.
Skin lesions may persist for months or years.50–52 Despite the
fact that CL is not a lethal disease and many lesions (especially
due to Old World species) heal spontaneously over months to
years, it is frequently associated with signiﬁcant morbidity and
may affect daily activities and social life when located on the
hands and face.14
Table 3
Differential diagnosis of leishmaniasis
Visceral leishmaniasis Cutaneous and mucosal leishmaniasis
Typhoid fever
Brucellosis
Subacute bacterial endocarditis
Miliary tuberculosis
Infectious mononucleosis
Malaria
Tropical splenomegaly syndrome
Histoplasmosis
Schistosomiasis
Trypanosomiasis
Leukemia
Lymphoma
Malnutrition
Tuberculosis
Non-tuberculous mycobacterial infection
Buruli ulcer
Leprosy
Syphilis
Yaws
Actinomycosis
Mycoses (histoplasmosis, coccidioidomycosis, blastomycosis, rhinosporidiosis)
Bacterial infection
Infected insect bites
Sarcoidosis
Skin cancer
Wegener’s granulomatosis
Foreign body
Nasal polyps
Septal deviation
A. Pavli, H.C. Maltezou / International Journal of Infectious Diseases 14 (2010) e1032–e1039e1036There is a potential concern of spreading of leishmanias to the
mucosal surfaces of the nose or mouth causing ML, which might
not be noticed until years after the initial skin lesions have healed.
ML occurs in 1–10% of CL cases 1–5 years after healing.1,2 Risk
factors for progression to ML include male sex, large or multiple
lesions, and lesions above the waist. Clinical manifestations
include chronic nasal congestion and bleeding, ulceration, and
septal granulomas. ML is not self-cured and may progress and
cause permanent or life-threatening complications such as
ulcerative destruction of the nose, mouth, pharynx, and larynx,
nasal septum perforation, and facial disﬁgurement, resulting in
social stigma.13,19,27 ML complicates almost exclusively New
World CL, and L. braziliensis is the species most often involved.
4. Diagnosis
Table 3 shows the differential diagnoses for all forms of
leishmaniasis. The differential diagnosis of leishmaniasis varies by
clinical form and area of acquisition of infection. Although very
uncommon in travelers, VL should be suspected in persons with a
relevant travel history to an endemic area and an unexplained
febrile illness, especially when hepatosplenomegaly and throm-
bocytopenia are present, in particular in migrants. Given the long
incubation period of leishmaniasis, it is critical for physicians to
consider travel to endemic areas that occurred several months or
years in the past. Risk factors for HIV infection should also be
considered, including sexual encounters, intravenous drug use,
and blood transfusions obtained abroad.53
Microscopic examination of bone marrow smears is the
reference method for the diagnosis of VL, and is associated with
>90% sensitivity rates in children and 70% in adults. Higher (>95%)
sensitivity rates are noted with spleen aspirates; however in the
context of profound thrombocytopenia, spleen sampling may
trigger life-threatening hemorrhage.3,54 The diagnosis can also be
conﬁrmed with molecular methods using various clinical speci-
mens (peripheral blood, bone marrow, spleen) with high
sensitivity and speciﬁcity rates.54,55 Serologic testing (direct
agglutination tests, enzyme-linked immunosorbent assay, and
indirect immunoﬂuorescence) are used in settings where other
diagnostic methods are not available, with high sensitivity and
speciﬁcity rates. Diagnostic cut-offs may depend on the area and
prevalence rates of asymptomatic infection.1 As a rule, IgG
antibodies remain detectable for several years after successful
treatment, and therefore serologic tests should not be used for
relapse cases.
Physicians should consider CL in persons with chronic, non-
healing skin lesions who have a travel history in endemic areas.Laboratory conﬁrmation of CL is achieved by detecting Leishmania
parasites through microscopic examination of stained skin speci-
mens because of its high speciﬁcity and ease. Punch biopsies with
tissue-impression smears can also be useful. Needle aspiration
from the margin of a lesion can yield ﬂuid for culture in special
medium to isolate the organism and identify the species.53
Serologic tests are not reliable for the diagnosis of CL.56 Polymerase
chain reaction (PCR) is useful for the diagnosis of CL and ML
because of low parasite numbers. PCR is themost commonmethod
available these days for the species-speciﬁc diagnosis of leish-
maniasis, which is important in choosing the right treatment.1
5. Treatment
An ideal anti-leishmanial agent should be effective, safe, easily
administered, and affordable; in practice, however, no such agent
is available. The choice of treatment is inﬂuenced by previous
experience as well as availability of a particular drug within a
country. Patients should be referred to specialized centers with
past experience. Treatment for VL should be started as soon as the
diagnosis is established.
The pentavalent antimonials meglumine antimoniate and
sodium stibogluconate remain the standard anti-leishmanial
treatment for VL in developing endemic areas. However, India is
an exception – their use has been abandoned here because of
widespread antimonial resistance, and they have been replaced
with conventional amphotericin B.57,58 Experience with antimo-
nials for almost 70 years indicates efﬁcacy rates of >90–95% and
low fatality and relapse rates.4,45,59,60 An advantage is their low
cost; the main disadvantages include intramuscular route of
administration, prolonged (20 mg/kg for 21–30 days) schedules,
and transient but occasionally life-threatening side effects, such as
cardiac arrhythmias, increased serum hepatic transaminases,
pancreatitis, and pneumonitis.4,57
Conventional amphotericin B has an excellent anti-leishmanial
activity, with >90% cure rates in Indian VL at a dose of 0.75 mg/kg
in 15-day regimens.61 Relapses are rare, except among HIV-
infected patients. Because of disadvantages including prolonged
hospitalization and administration, and frequent side effects
(nephrotoxicity, hypokalemia, and infusion-related fever and
chills), conventional amphotericin B does not offer any advantage
over pentavalent antimonials for use outside India.57 Lipid
formulations of amphotericin B (liposomal amphotericin B,
amphotericin B lipid complex, and amphotericin B cholesterol
dispersion) are selectively taken by the reticulo-endothelial
system of the host (where parasites replicate), offering the
advantage of a highly localized increased efﬁcacy with limited
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ﬁrst-line drug for VL in Europe, the USA, and other industrialized
countries, because of its rapid and up to 100% cure rates with 3–5-
day regimens, improved compliance of the patient, and reduced
health care costs.62 In HIV-co-infected patients, liposomal
amphotericin B is the ﬁrst drug of choice for treatment as well
as for secondary prophylaxis, because of its efﬁcacy and safety
proﬁle,46 while antimonials and conventional amphotericin B
should be avoided due to serious toxicity and intolerance.1
However, in poorly resourced endemic countries even short
courses of liposomal amphotericin B are unaffordable.7 In a recent
study in India, injectable paromomycin was shown to be non-
inferior to amphotericin B for the treatment of VL.63
Miltefosine is the ﬁrst oral anti-leishmanial drug. In a phase 4
trial of treatment with miltefosine in 1132 adults and children
with VL in India, 95% cure rates were noted, while adverse effects,
mainly gastrointestinal toxicity and increased hepatic transami-
nases and creatinine levels, were noted in 3% of patients.64
Currently, miltefosine is licensed in India, Germany, and Colombia.
It is administered at a dose of 100 mg/kg/day for 28 days in adults
50 kg, 50 mg/kg/day in adults weighting <50 kg, and 2.5 mg/kg/
day in children.7Miltefosine should not be administered towomen
who may become pregnant within 2 months after drug discontin-
uation because of concerns of teratogenicity.
Themanagement of CL is not standardized, since comparison of
therapeutic regimens is troublesome due to the fact that this form
of leishmaniasis is usually self-cured. Themanagement of travelers
with imported CL is further complicated by the fact that there are
no evidence-based data for this group of patients. Treatment is
recommended to accelerate cure, reduce scars, and prevent
mucosal dissemination in cases of New World CL.58 Systemic
treatment is indicated in cases of multiple or large (>4 cm) lesions,
when the face or a joint are affected, when lesions are present on
the hands or feet, for cosmetic reasons, and in immunosuppressed
patients.56 Pentavalent antimonials have been used for several
decades and are the gold standard of treatment. These agents are
administered either systemically or intralesionally.1 Intralesional
treatment is not approved by the US Food and Drug Administration
(FDA) and therefore is not in use in the USA.
Pentamidine, an aromatic diamidine, can be used as an
alternative to antimonials, and because of the long-lasting
experience with regards to efﬁcacy and safety is considered the
ﬁrst-line agent for L. guyanensis in French Guiana, Suriname, and
Brazil. Pentamidine is administered at a dose of 300 mg once
weekly for 3–5 weeks.58 Elevation of creatinine kinase has been
noticed withmuch higher doses, thus creatinine kinase and kidney
function have to be controlled before each injection.58,65 Glucose
serum levels should be checked, since one case of hyperglycemia
has been described after one dose of pentamidine at 200 mg.65
Preliminary studies show promising results with the use of
miltefosine in NewWorld CL and ML at a dosage of 2.5 mg/kg/day
for 28 days. The most important side effects include nausea,
vomiting, motion sickness, headache, and diarrhea. Elevated
transaminases and creatinine kinase have also been
reported.58,66,67 The imidazoles and the structurally-related
triazoles (ﬂuconazole, itraconazole, and ketoconazole) also dem-
onstrate anti-leishmanial activity. They can be administered orally
and have a good safety proﬁle,58 however they are effective against
a limited number of Leishmania species. A 6-week course of oral
ﬂuconazole was shown to be safe and a promising treatment for L.
major CL in Iran, with cure rates of 36% and 88% at days 50 and 90,
respectively.68 However, in a study conducted among travelers
with imported L. major CL, cure rates of 44.4% at day 50 were
recorded with the same regimen, comparable to published rates of
spontaneous healing.14 The effect of ﬂuconazole has been
questioned.14 Differences in efﬁcacy depend to a great extent onLeishmania species and area of infection. Oral miltefosine is
effective against L. major CL in Iran and L. braziliensis CL in Bolivia
with 92.9% and 88% cure rates, respectively, however the same
drug was found to be less effective in cases caused by the same
species in Guatemala.1,67,69
Azithromycin demonstrates anti-leishmanial activity in vitro
and has also been used for the treatment of CL andML, however its
use is limited to patients with treatment failure or contra-
indications for all other options, such as young children, pregnant
women, or patients with a severe underlying disease.70,71
Pentavalent antimonials administered for 20–28 days either
parenterally or intralesionally show high cure rates and remain the
mainstay of treatment for CL or ML, providing cure with a low rate
of recurrence.1,58,72 Satisfactory cure rates for CL are also achieved
with pentamidine.73,74 A recent meta-analysis concluded that
meglumine antimoniate is the drug of choice for ML with 88% cure
rates comparedwith 51% cure rates for stibogluconate.75 The use of
liposomal amphotericin B for CL andML has not been standardized
yet; it is mainly used in patients with resistance or contra-
indications for pentavalent antimonials.58
Topical application of immunomodulators (e.g., imiquimod
cream) in CL caused by L. peruviana or L. braziliensis has been shown
to improve the efﬁcacy of pentavalent antimonials or induce a
more rapid healing when given in combination. The combination
of oral pentoxifylline with antimonials has also been shown to
increase efﬁcacy.58,76
Physical treatment for CL such as heat, cryotherapy, laser, or a
combination of cryotherapy with intralesional meglumine anti-
moniate has been successfully applied in endemic countries.77–80
Local inﬁltration of pentavalent antimony maximizes the concen-
tration within lesions and has few systemic adverse effects,
however it does not reach metastatic lesions.81 Topical formula-
tions containing 15% paromomycin, an aminoglycoside antibiotic,
offer signiﬁcant advantages over systemic therapy, including ease
of administration, no systemic adverse effects, and reduced costs;
however, penetration into intact skin is weak.58 Elective surgery
and tattooing should be avoided for at least 12 months after any
treatment completion in order to avoid CL reactivation.82
6. Prevention
No vaccine against leishmaniasis is available. Travelers to
endemic areas should be advised that the only preventive
measures are those of protection against sandﬂy bite. These
include avoidance of outdoor activities, in particular from dusk to
dawn when sandﬂies are mostly active; protective clothes should
be worn and DEET (N,N-diethyl-meta-toluamide)-containing
repellents applied to exposed skin. Sandﬂies are weak ﬂiers and
therefore their movement may be inhibited by fans or ventilators.
Sleeping in air-conditioned or well-screened areas is also
advisable, as well as indoor spraying. Sandﬂies are smaller than
mosquitoes and they can pass through the holes of ordinary bed-
nets. The treatment of bed-nets with a pyrethroid-containing
insecticide (permethrin or deltamethrin) may protect against
indoor transmission.83 A randomized study in Venezuela evaluated
the implementation of pyrethroid-impregnated curtains in an
urban area with a 4% incidence of CL.83 A total of 2913 inhabitants
from569 homeswere enrolled. The use of pyrethroid-impregnated
curtains reduced the sandﬂy population and 12 months later the
incidence of CL was eliminated to 0%.83
7. Conclusions
Imported leishmaniasis is an uncommon but emerging infec-
tious disease among international travelers. The management of
leishmaniasis in developed, non-endemic countries is a challenge
A. Pavli, H.C. Maltezou / International Journal of Infectious Diseases 14 (2010) e1032–e1039e1038because of the unfamiliarity of physicians with its wide clinical
spectrum, the diagnostic modalities, and available treatment
options. Leishmaniasis should be considered in travelers with
compatible clinical ﬁndings and a history of travel to an endemic
area, even months or years ago. Information regarding leishmani-
asis and appropriate protective measures should be offered to
adventure travelers, military personnel, and immigrants likely to
be exposed to sandﬂies in endemic areas.
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